Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Dermatology · 2024
DOI: 10.1159/000535285 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Dermatology, 2024. Verfasst von Jacob P Thyssen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Wound Healing, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden.
Objectives
The aim of the study was to evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.
Methods
This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item (“How painful was your skin over the past 24 h?”) on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children’s Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed-effects repeated measures modeling.
Results
A total of 1,822 patients (monotherapy pool, n = 942; JADE COMPARE, n = 595; and JADE TEEN, n = 285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs. 12%; week 12), JADE COMPARE (72% and 52% vs. 26%; week 16), and JADE TEEN (51% and 60% vs. 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score <2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.
Conclusion
Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Wound Healing, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
- Barts Health NHS Trust, London, UK.
- Center for Chronic Pruritus, Münster University Hospital, Münster, Germany.
- Pediatric Dermatology, Hospital Universitario Austral, Pilar, Argentina.
- University Hospital of Brest, Brest, France.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Zitieren
APA
Thyssen, J. P., Bewley, A., Ständer, S., Castro, C., Misery, L., Kim, B. S., Biswas, P., Chan, G., Myers, D. E., Watkins, M., Alderfer, J., Güler, E., & Silverberg, J. I. (2024). Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis. Dermatology. https://doi.org/10.1159/000535285
Vancouver
Thyssen JP, Bewley A, Ständer S, Castro C, Misery L, Kim BS, et al. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis. Dermatology. 2024. doi:10.1159/000535285
BibTeX
@article{Thyssen2024,
author = {Thyssen, Jacob P and Bewley, Anthony and Ständer, Sonja and Castro, Carla and Misery, Laurent and Kim, Brian S and Biswas, Pinaki and Chan, Gary and Myers, Daniela E and Watkins, Melissa and Alderfer, Justine and Güler, Erman and Silverberg, Jonathan I},
title = {Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis},
journal = {Dermatology},
year = {2024},
doi = {10.1159/000535285}
}
EUVIMED